Get Immunic alerts:Immunic, Inc. (NASDAQ:IMUX – Free Report) – Analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Immunic in a note issued to investors on Monday, September 29th. Chardan Capital has a “Buy” rating and a $13.00 price objective on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Thursday, September 25th. Immunic Price PerformanceIMUX opened at $0.96 on Wednesday. 683 Capital Management LLC raised its position in shares of Immunic by 28.6% during the 1st quarter.